A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

  • STATUS
    Not Recruiting
  • days left to enroll
    37
  • participants needed
    114
  • sponsor
    KalVista Pharmaceuticals, Ltd.
Send
Updated on 22 September 2023
See if I qualify
angioedema
c1 inhibitor (human)

Summary

This study is a randomized, double-blind, placebo-controlled, phase III, three-way crossover clinical trial evaluating the efficacy and safety of KVD900, in the treatment of hereditary angioedema attacks in adolescent and adult Patients

Details
Condition Hereditary Angioedema
Treatment Placebo, KVD900 600 mg, KVD900 300 mg
Clinical Study IdentifierNCT05259917
SponsorKalVista Pharmaceuticals, Ltd.
Last Modified on22 September 2023

Similar trials to consider

Browse trials for

angioedema
c1 inhibitor (human)

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note